These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 9211574

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Olanzapine in the treatment of resistant depression.
    Caetano D, Caetano SC.
    Aust N Z J Psychiatry; 2005; 39(1-2):108-9. PubMed ID: 15660713
    [No Abstract] [Full Text] [Related]

  • 23. [Narcoleptic syndrome as a possible side effect of paroxetine].
    Alonso H, Ortí-Pareja M, Jiménez-Jiménez FJ.
    Rev Neurol; 2005; 39(11):1092. PubMed ID: 15597274
    [No Abstract] [Full Text] [Related]

  • 24. Hypothermia in a patient receiving risperidone and paroxetine.
    Al Chekakie MO, Ketz JM, Whinney CM.
    J Clin Psychopharmacol; 2006 Jun; 26(3):332-3. PubMed ID: 16702902
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Rifampin-zotepine interaction reduces effectiveness of antipsychotic drugs in a stable schizophrenia patient.
    Pai MS, Yang SN, Shiah IS.
    Psychiatry Clin Neurosci; 2012 Oct; 66(6):538. PubMed ID: 23066778
    [No Abstract] [Full Text] [Related]

  • 27. Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.
    Arnone D, Hansen L, Kerr JS.
    J Psychopharmacol; 2002 Dec; 16(4):395-7. PubMed ID: 12503843
    [Abstract] [Full Text] [Related]

  • 28. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 29. Serotonin syndrome after lithium add-on medication to paroxetine.
    Sobanski T, Bagli M, Laux G, Rao ML.
    Pharmacopsychiatry; 1997 May; 30(3):106-7. PubMed ID: 9211572
    [Abstract] [Full Text] [Related]

  • 30. [Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics].
    Harada T, Otsuki S, Fujiwara Y.
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():41-4. PubMed ID: 1683339
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR.
    DeVane CL.
    Psychopharmacol Bull; 2003 Sep; 37 Suppl 1():29-41. PubMed ID: 14566199
    [Abstract] [Full Text] [Related]

  • 32. Three cases of alopecia areata induced by zotepine.
    Kubota T, Ishikura T, Jibiki I.
    Acta Neurol (Napoli); 1993 Jun; 15(3):200-3. PubMed ID: 7901970
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN.
    Psychopharmacol Bull; 2003 Jun; 37 Suppl 1():176-86. PubMed ID: 14566210
    [Abstract] [Full Text] [Related]

  • 34. [The serotonin syndrome].
    Kozian R.
    Psychiatr Prax; 2005 Oct; 32(7):367-9. PubMed ID: 16220422
    [Abstract] [Full Text] [Related]

  • 35. [Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate].
    Vergouwen AC, Bakker A.
    Ned Tijdschr Geneeskd; 2002 Apr 27; 146(17):811-2. PubMed ID: 12014241
    [Abstract] [Full Text] [Related]

  • 36. [Paroxetine-induced neuroleptic malignant syndrome].
    Heinemann F, Assion HJ, Hermes G, Ehrlich M.
    Nervenarzt; 1997 Aug 27; 68(8):664-6. PubMed ID: 9380213
    [Abstract] [Full Text] [Related]

  • 37. The treatment of depression with paroxetine in psychiatric practice in Germany: the possibilities and current limitations of drug monitoring.
    Zaninelli R, Meister W.
    Pharmacopsychiatry; 1997 Jan 27; 30(1 Suppl):9-20. PubMed ID: 9035223
    [Abstract] [Full Text] [Related]

  • 38. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
    Dieterle DM, Müller-Spahn F, Ackenheil M.
    Fortschr Neurol Psychiatr; 1991 Sep 27; 59 Suppl 1():18-22. PubMed ID: 1683334
    [Abstract] [Full Text] [Related]

  • 39. [Paroxetine in the treatment of depressive disorders (pilot study)].
    Svestka J, Novotný V, Kamenická V, Obrovská V, Cesková E.
    Cesk Psychiatr; 1995 Jul 27; 91(3):135-42. PubMed ID: 7553946
    [Abstract] [Full Text] [Related]

  • 40. [Bradycardia after beginning therapy with metoprolol and paroxetine].
    König F, Häfele M, Hauger B, Löble M, Wössner S, Wolfersdorf M.
    Psychiatr Prax; 1996 Sep 27; 23(5):244-5. PubMed ID: 8992519
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.